Budget Amount *help |
¥175,240,000 (Direct Cost: ¥134,800,000、Indirect Cost: ¥40,440,000)
Fiscal Year 2022: ¥38,480,000 (Direct Cost: ¥29,600,000、Indirect Cost: ¥8,880,000)
Fiscal Year 2021: ¥38,480,000 (Direct Cost: ¥29,600,000、Indirect Cost: ¥8,880,000)
Fiscal Year 2020: ¥38,480,000 (Direct Cost: ¥29,600,000、Indirect Cost: ¥8,880,000)
Fiscal Year 2019: ¥38,480,000 (Direct Cost: ¥29,600,000、Indirect Cost: ¥8,880,000)
Fiscal Year 2018: ¥21,320,000 (Direct Cost: ¥16,400,000、Indirect Cost: ¥4,920,000)
|
Outline of Final Research Achievements |
We have established various cellular interaction analysis methods to develop new chemical probes that bind strongly to ubiquitin decoders and shuttle molecules and modulate their functions. Using split-luciferase, chemical arrays, microscale thermophoresis, and TR-FRET methods, we have discovered inhibitors of ubiquitin-decoder interactions and novel ligands for cystic fibrosis-related E3 ubiquitin ligases RFFL and RNF5. We also developed a probe that induces cancer cell-specific ubiquitination of intracellular proteins using a molecule that efficiently reacts with acrolein, which is overproduced in cancer. Furthermore, we have elucidated a novel quality control mechanism that suppresses the expression of aggregation-prone proteins translated from intron-derived sequences resulting from splicing errors.
|